# Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

> **NCT06957561** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 30 (estimated)

## Conditions studied

- Bladder Cancer
- Muscle-invasive Bladder Cancer

## Interventions

- **DRUG:** Disitamab Vedotin Injection
- **DRUG:** Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）
- **PROCEDURE:** Radical Cystectomy with Pelvic Lymph Node Dissection

## Key facts

- **NCT ID:** NCT06957561
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04-30
- **Primary completion:** 2026-05-01
- **Final completion:** 2029-05-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06957561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06957561, "Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06957561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*